Skip to main content
Caplight Logo









TechnoPhage

TechnoPhage

Private
LisbonHealthcare & Life Scienceshttps://technophage.pt/

Last Round

Grant

Jul 25, 2022

Total Funding Raised

$5.6M

Company Overview

TechnoPhage is a biotechnology and drug discovery company that develops innovative therapies for unmet medical needs in infection, neurosciences, and ophthalmology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

phage therapybacteriophage technologyantimicrobial resistanceantibiotic resistancesuperbug treatmentclinical-stage biopharmadrug discoverydiabetic foot infectionbiologics developmentGood Manufacturing PracticeGMPFDA Fast Track designationCDMO servicesCRO servicescontract manufacturingneuroscienceophthalmology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

TechnoPhage Comparables

Compare TechnoPhage with similar companies based on industry and business-model similarity.

TechnoPhage comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BiomX Inc.
79%
NexaBiome
78%
PHAXIAM Therapeutics S.A.
78%

TechnoPhage Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJul 25, 2022
AcceleratorJan 1, 2020
GrantFeb 1, 2015

Key People

Founding team and executive leadership

Miguel Garcia

CEO

Executive Team

Sofia Corte-Real

Deputy CEO, Chief Scientific Officer

Executive Team

TechnoPhage Investors

Notable investors and investment history

TechnoPhage investors
InvestorRounds
European CommissionGrant
Portuguese GovernmentGrant
Johnson & Johnson Innovation - JLABSAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 21, 2026

    Grew 15% QoQ from 26 to 30 employees.

  • Jun 7, 2025

    Grew 22% QoQ, from 27 to 33 employees.

TechnoPhage Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

TechnoPhage Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about TechnoPhage's valuation, stock price, and market status.

Firmographic Details

HeadquartersLisbon
Employee Range28
Year Founded2005
Last FundingJul 25, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.